TerminatedNCT02075047

Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolarity type I

Medication studyAges 10–17United States + Ukraine

The study in practice

Understand this study

This study is for people with bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria apply.

Listed locations: Dothan and 49 more locationsSee all locations and recruitment
Study phase: Phase 3

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: May 23, 2014

Recruitment status: Terminated
Enrollment listed in the registry: 171
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Drug
Study phase: Phase 3
Locations: United States, Ukraine
Age range: From 10 Years to 17 Years
Official registry ID: NCT02075047
Official title: Show the full official title
A PHASE 3, MULTICENTER, FOUR-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY TRIAL OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (CURRENT OR MOST RECENT EPISODE MANIC)

Terminated

Dothan, United States · Little Rock, United States · Anaheim, United States

33 more locations

FAQ

Who is behind this study?

The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Does this study involve medication?

Yes. The study involves medication, including placebo oral capsules and ziprasidone oral capsules.

Who can participate?

This study is for people with bipolarity. Listed age limits: 10 years to 17 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.